- Home
- FENC vs RLTY Comparison
FENC vs RLTY Comparison
Compare FENC & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$8.03
Company Overview
Basic Information| Metric | FENC | RLTY |
|---|---|---|
| Founded | 1996 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.3M | 245.8M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FENC | RLTY |
|---|---|---|
| Price | $8.03 | $15.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 108.5K | 82.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.35% |
| EPS Growth | ★ 96.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,538,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.69 | N/A |
| 52 Week Low | $4.68 | $12.90 |
| 52 Week High | $9.92 | $15.97 |
Technical Indicators
Market Signals| Indicator | FENC | RLTY |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 62.74 |
| Support Level | $7.45 | $14.95 |
| Resistance Level | $8.09 | N/A |
| Average True Range (ATR) | 0.45 | 0.23 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 29.14 | 73.44 |
Price Performance
Historical Comparison FENC
RLTY
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.